Philippe JEAN-PIERRE

---

• Type de publi. : Article dans une revue
• Date de publi. : 05/04/2024
• Auteurs : Penelope JordanCamille VerebiBerenice HervéSandrine PerolZeina ChakhtouraCarine CourtillotAnne BachelotDaphne KarilaCeline RenardVirginie GrouthierStanislas Mulot de la CroixValerie BernardCorinne FouveautAude Brac de la PerrièreSophie Jonard-CatteauPhilippe TouraineGenevieve Plu-BureauJean Michel DupontSophie Christin-MaitreThierry Bienvenu
• Organismes : Hôpital Cochin [AP-HP] Université Sorbonne Paris Cité Hôpital Cochin [AP-HP] Université Sorbonne Paris Cité Hôpital Cochin [AP-HP] Université Sorbonne Paris Cité Hôpital Cochin [AP-HP] Université Sorbonne Paris Cité CHU Pitié-Salpêtrière [AP-HP] Sorbonne Université CHU Pitié-Salpêtrière [AP-HP] Sorbonne Université CHU Pitié-Salpêtrière [AP-HP] Sorbonne Université CHU Saint-Antoine [AP-HP] Sorbonne Université CHU Caen Normandie – Centre Hospitalier Universitaire de Caen Normandie Centre Hospitalier Universitaire de Bordeaux CHU Caen Normandie – Centre Hospitalier Universitaire de Caen Normandie Centre Hospitalier Universitaire de Bordeaux Hôpital Cochin [AP-HP] Université Sorbonne Paris Cité Hospices Civils de Lyon Centre de Recherche Jean-Pierre AUBERT Neurosciences et Cancer - U837 Hôpital Jeanne de Flandre [Lille] CHU Pitié-Salpêtrière [AP-HP] Sorbonne Université Hôpital Cochin [AP-HP] Université Sorbonne Paris Cité Hôpital Cochin [AP-HP] Université Sorbonne Paris Cité CHU Saint-Antoine [AP-HP] Sorbonne Université Hôpital Cochin [AP-HP]
• Publié dans Clinical Genetics le 30/10/2020

---

Résumé : Pathogenic germline variants in the FOXL2 gene are associated with Blepharophimosis, Ptosis, and Epicanthus Inversus syndrome (BPES) in humans, an autosomal dominant condition. Two forms of BPES have emerged: (i) type I (BPES-I), characterized by ocular signs and primary ovarian failure (POI), and (ii) type II (BPES-II) with no systemic associations. This study aimed to compare the distribution of FOXL2 variants in idiopathic POI/DOR (diminished ovarian reserve) and both types of BPES, and to determine the involvement of FOXL2 in non-syndromic forms of POI/DOR. We studied the whole coding region of the FOXL2 gene using next-generation sequencing in 1282 patients with non-syndromic POI/DOR. Each identified FOXL2 variant was compared to its frequency in the general population, considering ethnicity. Screening of the entire coding region of the FOXL2 gene allowed us to identify 10 different variants, including nine missense variants. Of the patients with POI/DOR, 14 (1%) carried a FOXL2 variant. Significantly, six out of nine missense variants (67%) were overrepresented in our POI/DOR cohort compared to the general or specific ethnic subgroups. Our findings strongly suggest that five rare missense variants, mainly located in the C-terminal region of FOXL2 are high-risk factors for non-syndromic POI/DOR, though FOXL2 gene implication accounts for approximately 0.54% of non-syndromic POI/DOR cases. These results support the implementation of routine genetic screening for patients with POI/DOR in clinical settings.

---

Fichiers liés : Clinical Genetics - 2024 - Jordan - Shifting the landscape Dominant C‐terminal rare missense FOXL2 variants in.pdf

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 05/04/2024
• Auteurs : Margherita FabbriVanessa RousseauJean-Christophe CorvolAgnès SommetFlorence TubachYann De RyckeNathalie BertilleYajiththa SelvarasaStephanie CarvalhoVéronique ChaigneauChristine Brefel-CourbonFabienne Ory-MagneSamuel TessierFazia Mélissa TirMatthieu BereauWassilios MeissnerClaire ThiriezAna MarquesPhilippe RemyVincent SchneiderElena MoroLuc DefebvreJean-Luc HouetoStéphane PrangeAlexandre EusebioChristian GenySolène FrismandPhilippe DamierCaroline Giordana ReutherGiovanni CastelnovoIsabelle BenatruAnne Doe de MaindrevilleSophie DrapierDavid MaltêteOuhaid Lagha-BoukbizaOlivier RascolMickael AubignatEloi MagninPr Pierre BurbaudPr Dominique GuehlAlexandra Foubert-SamierBrice LaurensThomas BoraudSylvain VergnetDavid BendetowiczThomas PalpacuerBérengère DebillyPhilippe DerostCharlotte BealHayet SalhiAlice DormeuilAimée PetitAlban GravierGwendoline DupontLucie GarnierValérie FraixAnna CastriotoSara MeoniNicolas CarriereTeodor DanailaChloé LaurencinStéphane ThoboisJean-Philippe AzulayFrédérique FluchereMahmoud CharifMarie-Christine PicotLucie HopesAnne-Gaelle CorbilleTiphaine RouaudPascal DerkinderenCosmin AlecuCharlotte HeraudMarie de VerdalBertrand DegosGraziella MangoneSara SambinAymeric LanoreThomas CourtinLouise-Laure MarianiDavid BendetowiczFouad KhouryPoornima MenonFlorence Cormier-DequaireEmmanuel Flamand-RozeDavid GrabliElodie HainqueMarie VidhailletAurélie MeneretCécile DelormeCendrine FoucardFlorian von RaisonAlexis ElbazAndreas HartmannVincent LeclercqSolène AnsquerFrederique LehMarion LeclercqGuillaume CostentinChristine Brefel CourbonClemence LeungHélène CatalaAstrid CauselEmilie GaiffeSandrine DupouySandrine VillarsWei-Ho LaiRachida BariDamien ChevanneElodie DurandIsabelle RieuStephane BernardCorinne GarsaultNoel BoudjemaPascale GrebentAndrea KistnerPierre PelissierValérie SantraineThomas GaudinPierre BoutetCatherine CaireManel NouiraClaudia VernaAmory JardelSalomé PuisieuxGuillemette ClementLili Le MonnierRégis FrenaisSéverine Le DilyRachel ChaigneauVanessa FerrierElodie DavidLeslie FraElsa FoucaranCarole Dongmo-KenfackFlorence BeauzorMickael LeSonia MessarSophie LiotÉmilie RaboisMargaux Bonnaire-VerdierFrançoise KestensRozenn GourhanSandra Lopez-AlfaroJean-François HouvenaghelMélanie AlexandreChristine BourdonnaisLinda VernonAhmed BoumedieneCéline JulieAurette LobsteinNadine LongatoMarie-Pierre MitterleClélie PhilipsHugo RummelStéphanie BrasEstelle HarrochClaudia Gillet
• Organismes : Centre d'investigation clinique de Toulouse Centre d’Excellence en Maladies Neurodégénératives Toulouse NeuroImaging Center Plateforme F-CRIN Centre d'investigation clinique de Toulouse Plateforme F-CRIN Institut du Cerveau = Paris Brain Institute Centre d'investigation clinique Neurosciences [CHU Pitié Salpêtrière] Centre d'investigation clinique de Toulouse Institut Pierre Louis d'Epidémiologie et de Santé Publique Institut Pierre Louis d'Epidémiologie et de Santé Publique Institut Pierre Louis d'Epidémiologie et de Santé Publique Plateforme F-CRIN Institut du Cerveau = Paris Brain Institute Centre d'investigation clinique Neurosciences [CHU Pitié Salpêtrière] Plateforme F-CRIN Institut du Cerveau = Paris Brain Institute Centre d'investigation clinique Neurosciences [CHU Pitié Salpêtrière] Plateforme F-CRIN Plateforme F-CRIN Centre d'investigation clinique de Toulouse Plateforme F-CRIN Département Neurologie [CHU Toulouse] Toulouse NeuroImaging Center Centre Régional de PharmacoVigilance [CHU Toulouse] Service de neurologie [Amiens] Laboratoire de Neurosciences Fonctionnelles et Pathologies - UR UPJV 4559 Plateforme F-CRIN Service de Neurologie [CHRU Besançon] Centre de référence de l’atrophie multisystématisée [CHU Toulouse] Institut des Maladies Neurodégénératives [Bordeaux] University of Otago [Dunedin, Nouvelle-Zélande] New Zealand Brain Research Institute Plateforme F-CRIN Service de Neurologie [CHU Caen] Plateforme F-CRIN Neuro-Psycho Pharmacologie des Systèmes Dopaminergiques sous-corticaux Plateforme F-CRIN Institut Mondor de Recherche Biomédicale Plateforme F-CRIN Service de Neurologie générale, vasculaire et dégénérative (CHU de Dijon) Plateforme F-CRIN Unité Médicale des Troubles du Mouvement European Academy of Neurology [Vienna, Austria] Plateforme F-CRIN Lille Neurosciences & Cognition - U 1172 Plateforme F-CRIN Epidémiologie des Maladies Chroniques en zone tropicale Service de neurologie C, centre expert parkinson Université Claude Bernard Lyon 1 Institut des sciences cognitives Marc Jeannerod - Centre de neuroscience cognitive - UMR5229 Plateforme F-CRIN Service de neurologie et pathologie du mouvement Plateforme F-CRIN EuroMov - Digital Health in Motion Département de Neurologie [Hôpital Gui de Chauliac - CHU Montpellier] Plateforme F-CRIN Centres Mémoire de Ressources et de Recherche [CHRU Nancy] Plateforme F-CRIN Centre d'investigation clinique (CIC) de Nantes -CIC Plurithématique Plateforme F-CRIN Service de Neurologie [CHU Nice] Plateforme F-CRIN Service de Neurologie [CHU Nimes] Plateforme F-CRIN CIC Poitiers – Centre d'investigation clinique de Poitiers (CIC 1402) Plateforme F-CRIN Hôpital Maison Blanche Plateforme F-CRIN Centre Hospitalier Universitaire de Rennes [CHU Rennes] = Rennes University Hospital [Pontchaillou] Centre d'Investigation Clinique [Rennes] Plateforme F-CRIN Service de neurologie [Rouen] Neuroendocrine, Endocrine and Germinal Differentiation Communication Plateforme F-CRIN Hôpital Maison Blanche Centre d'investigation clinique de Toulouse Centre d’Excellence en Maladies Neurodégénératives Toulouse NeuroImaging Center Plateforme F-CRIN Bordeaux population health
• Publié dans Journal of Neural Transmission le 25/10/2020

---

Résumé : Objective: To assess amantadine use and associated factors in the patients with Parkinson's disease (PD). Background: Immediate-release amantadine is approved for the treatment of PD and is largely used in clinical practice to treat "levodopa-induced dyskinesia (LIDs). Its use varies according to countries and PD stages. The prospective NS-Park cohort collects features of PD patients followed by 26 French PD Expert Centres. Methods: Variables used for the analyses included demographics, motor and non-motor PD symptoms and motor complications [motor fluctuations (MFs), LIDs)], antiparkinsonian pharmacological classes and levodopa equivalent daily dose (LEDD). We evaluated: (i) prevalence of amantadine use and compared clinical features of amantadine users vs. non-users (cross-sectional analysis); (ii) factors associated with amantadine initiation (longitudinal analysis); (iii) amantadine effect on LIDs, MFs, apathy, impulse control disorders and freezing of gait (Fog) (longitudinal analysis). Results: Amantadine use prevalence was 12.6% (1,585/12,542, median dose = 200 mg). Amantadine users were significantly younger, with longer and more severe PD symptoms, greater LEDD and more frequent use of device-aided/surgical treatment. Factors independently associated with amantadine initiation were younger age, longer PD duration, more frequent LIDs, MFs and FoG, higher LEDD and better cognitive function. 9 of the 658 patients on amantadine had stopped it at the following visit, after 12-18 months (1.3%). New users of amantadine presented a higher improvement in LIDs and MF compared to amantadine never users. Conclusions: About 12% of PD patients within the French NS-Park cohort used amantadine, mostly those with younger age and more severe PD. Amantadine initiation was associated with a subsequent reduction in LIDs and MFs.

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 04/04/2024
• Auteurs : Sébastien PettonFabrice PernetValérian Le RoyMatthias HuberSophie MartinÉric MacéYann BozecStéphane LoiselPeggy Rimmelin-MauryÉmilie GrossteffanMichel RepecaudLoïc QuemenerMichael RethoSoazig Manac'HMathias PapinPhilippe PineauThomas Lacoue-LabartheJonathan DebordeLouis CostesPierre PolsenaereLoïc RigouinJérémy BenhamouLaure GouriouJoséphine LequeuxNathalie LabourdetteNicolas SavoyeGrégory MessiaenElodie FoucaultVincent OuisseMarion RichardFranck LagardeFlorian VoronValentin KempfSébastien MasLéa GiannecchiniFrancesca VidussiBehzad MostajirYann LereddeSamir AlliouaneJean-Pierre GattusoFrédéric Gazeau
• Organismes : Laboratoire des Sciences de l'Environnement Marin (LEMAR) Laboratoire des Sciences de l'Environnement Marin (LEMAR) Laboratoire des Sciences de l'Environnement Marin (LEMAR) Laboratoire des Sciences de l'Environnement Marin (LEMAR) Adaptation et diversité en milieu marin Adaptation et diversité en milieu marin Adaptation et diversité en milieu marin Adaptation et diversité en milieu marin Institut Universitaire Européen de la Mer Institut Universitaire Européen de la Mer Unité Recherches et Développements Technologiques Unité Recherches et Développements Technologiques Laboratoire Environnement Ressources Morbihan Pays de Loire Laboratoire Environnement Ressources Morbihan Pays de Loire Unité Expérimentale Mollusques Marins Atlantique LIttoral ENvironnement et Sociétés LIttoral ENvironnement et Sociétés Laboratoire Environnement Ressources des Pertuis Charentais Laboratoire Environnement Ressources des Pertuis Charentais Laboratoire Environnement Ressources des Pertuis Charentais Laboratoire Environnement Ressources d'Arcachon Ecosystèmes Insulaires Océaniens (UMR 241) Laboratoire Environnement Ressources d'Arcachon Pluridisciplinarité au service de l’observation et de la recherche en environnement et astronomie Earth and Planetary Observation Centre Earth and Planetary Observation Centre MARine Biodiversity Exploitation and Conservation - MARBEC MARine Biodiversity Exploitation and Conservation - MARBEC MARine Biodiversity Exploitation and Conservation - MARBEC MARine Biodiversity Exploitation and Conservation - MARBEC MARine Biodiversity Exploitation and Conservation - MARBEC Observatoire de REcherche Méditerranéen de l'Environnement Observatoire de REcherche Méditerranéen de l'Environnement Observatoire de REcherche Méditerranéen de l'Environnement Observatoire de REcherche Méditerranéen de l'Environnement MARine Biodiversity Exploitation and Conservation - MARBEC MARine Biodiversity Exploitation and Conservation - MARBEC Géosciences Montpellier Laboratoire d'océanographie de Villefranche Laboratoire d'océanographie de Villefranche Institut du Développement Durable et des Relations Internationales Laboratoire d'océanographie de Villefranche
• Publié dans Earth System Science Data le 23/10/2020

---

Résumé : Since the beginning of the industrial revolution, atmospheric carbon dioxide (CO2) concentrations have risen steadily and have induced a decrease of the averaged surface ocean pH by 0.1 units, corresponding to an increase in ocean acidity of about 30 %. In addition to ocean warming, ocean acidification poses a tremendous challenge to some marine organisms, especially calcifiers. The need for long-term oceanic observations of pH and temperature is a key element to assess the vulnerability of marine communities and ecosystems to these pressures. Nearshore productive environments, where a large majority of shellfish farming activities are conducted, are known to present pH levels as well as amplitudes of daily and seasonal variations that are much larger than those observed in the open ocean. Yet, to date, there are very few coastal observation sites where these parameters are measured simultaneously and at high frequency. To bridge this gap, an observation network was initiated in 2021 in the framework of the CocoriCO2 project. Six sites were selected along the French Atlantic and Mediterranean coastlines based on their importance in terms of shellfish production and the presence of high- and low-frequency monitoring activities. At each site, autonomous pH sensors were deployed, both inside and outside shellfish production areas, next to high-frequency CTD (conductivity–temperature–depth) probes operated through two operating monitoring networks. pH sensors were set to an acquisition rate of 15 min, and discrete seawater samples were collected biweekly in order to control the quality of pH data (laboratory spectrophotometric measurements) as well as to measure total alkalinity and dissolved inorganic carbon concentrations for full characterization of the carbonate system. While this network has been up and running for more than 2 years, the acquired dataset has already revealed important differences in terms of pH variations between monitored sites related to the influence of diverse processes (freshwater inputs, tides, temperature, biological processes). Data are available at https://doi.org/10.17882/96982 (Petton et al., 2023a).

---

Fichiers liés : essd-16-1667-2024.pdf

---

Source

---

• Type de publi. : Communication dans un congrès
• Date de publi. : 04/04/2024
• Auteurs : Jean-Philippe GoiranCamille GonçalvesCécile VittoriGilles BrocardAdele BertiniMarco Leporati PersianoFabio CianchiAlessandro ConfortiGuillaume JouveLaurent MattioChristophe BenechLionel DarrasQuentin VitaleBrahimsamba BomouPierre SabatierMaxime DebretKevin JacqAnne-Lise DevelleChristine OberlinGilles van Heems
• Organismes : ARCHEORIENT - Environnements et sociétés de l'Orient ancien ARCHEORIENT - Environnements et sociétés de l'Orient ancien Laboratoire Image, Ville, Environnement ARCHEORIENT - Environnements et sociétés de l'Orient ancien Histoire et Sources des Mondes antiques ARCHEORIENT - Environnements et sociétés de l'Orient ancien Università degli Studi di Firenze = University of Florence = Université de Florence Region Toscane, Italie Oasi WWF Maremma Istituto per lo studio degli impatti Antropici e Sostenibilità in ambiente marino Exail (iXblue) Exail (iXblue) ARCHEORIENT - Environnements et sociétés de l'Orient ancien ARCHEORIENT - Environnements et sociétés de l'Orient ancien ARCHEORIENT - Environnements et sociétés de l'Orient ancien Études et valorisations archéologiques Institut des sciences de la terre [Lausanne] Environnements, Dynamiques et Territoires de Montagne Morphodynamique Continentale et Côtière Environnements, Dynamiques et Territoires de Montagne Laboratoire d'Informatique, Systèmes, Traitement de l'Information et de la Connaissance Environnements, Dynamiques et Territoires de Montagne Archéologie et Archéométrie Université Lumière - Lyon 2 Histoire et Sources des Mondes antiques Centre Alfred Ernout - Linguistique latine

---

Fichiers liés : Conférence Urbi et Orb_JournéesIMU2024.pdf

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 04/04/2024
• Auteurs : Wassilios MeissnerPhilippe RemyCaroline GiordanaDavid MaltêtePascal DerkinderenJean-Luc HouétoMathieu AnheimIsabelle BenatruThomas BoraudChristine Brefel-CourbonNicolas CarrièreHélène CatalaOlivier ColinJean-Christophe CorvolPhilippe DamierEstelle DellapinaDavid DevosSophie DrapierMargherita FabbriVanessa FerrierAlexandra Foubert-SamierSolène Frismand-KryloffAurore GeorgetChristine GermainStephan GrimaldiClémence HardyLucie HopesPierre KrystkowiakBrice LaurensRomain LefaucheurLouise-Laure MarianiAna MarquesClaire MarseFabienne Ory-MagneVincent RigalleauHayet SalhiAmandine SaubionSimon StottClaire ThalamasClaire ThiriezFazia Mélissa TirRichard WyseAntoine BenardOlivier Rascol
• Organismes : Institut des Maladies Neurodégénératives [Bordeaux] CHU Henri Mondor [Créteil] Institut Mondor de Recherche Biomédicale Service de Neurologie [CHU Nice] Neuroendocrine, Endocrine and Germinal Differentiation Communication The Enteric Nervous System in gut and brain disorders [U1235] Centre d'investigation clinique (CIC) de Nantes -CIC Plurithématique CHU Limoges Hôpital de Hautepierre [Strasbourg] Centre hospitalier universitaire de Poitiers = Poitiers University Hospital Institut des Maladies Neurodégénératives [Bordeaux] Imagerie cérébrale et handicaps neurologiques Centre Hospitalier Régional Universitaire [CHU Lille] Institut du Cerveau = Paris Brain Institute Centre d’Investigation Clinique de Nantes Centre Hospitalier Universitaire de Toulouse Université Toulouse III - Paul Sabatier Centre d'investigation clinique de Toulouse Laboratoire de Neurosciences Fonctionnelles et Pathologies - UR UPJV 4559 Centre d'Investigation Clinique [Rennes] Centre Hospitalier Universitaire de Rennes [CHU Rennes] = Rennes University Hospital [Pontchaillou] Centre d'investigation clinique de Toulouse Centre Hospitalier Universitaire de Toulouse Emergence des Pathologies Virales Bordeaux population health Service de neurologie [Amiens] CHirurgie, IMagerie et REgénération tissulaire de l’extrémité céphalique - Caractérisation morphologique et fonctionnelle - UR UPJV 7516 Bordeaux population health Service de neurologie [Amiens] Laboratoire de Neurosciences Fonctionnelles et Pathologies - UR UPJV 4559 Bordeaux population health
• Publié dans New England Journal of Medicine le 29/10/2020

---

Résumé : Background: Lixisenatide, a glucagon-like peptide-1 receptor agonist used for the treatment of diabetes, has shown neuroprotective properties in a mouse model of Parkinson's disease.Methods: In this phase 2, double-blind, randomized, placebo-controlled trial, we assessed the effect of lixisenatide on the progression of motor disability in persons with Parkinson's disease. Participants in whom Parkinson's disease was diagnosed less than 3 years earlier, who were receiving a stable dose of medications to treat symptoms, and who did not have motor complications were randomly assigned in a 1:1 ratio to daily subcutaneous lixisenatide or placebo for 12 months, followed by a 2-month washout period. The primary end point was the change from baseline in scores on the Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) part III (range, 0 to 132, with higher scores indicating greater motor disability), which was assessed in patients in the on-medication state at 12 months. Secondary end points included other MDS-UPDRS subscores at 6, 12, and 14 months and doses of levodopa equivalent.Results: A total of 156 persons were enrolled, with 78 assigned to each group. MDS-UPDRS part III scores at baseline were approximately 15 in both groups. At 12 months, scores on the MDS-UPDRS part III had changed by -0.04 points (indicating improvement) in the lixisenatide group and 3.04 points (indicating worsening disability) in the placebo group (difference, 3.08; 95% confidence interval, 0.86 to 5.30; P = 0.007). At 14 months, after a 2-month washout period, the mean MDS-UPDRS motor scores in the off-medication state were 17.7 (95% CI, 15.7 to 19.7) with lixisenatide and 20.6 (95% CI, 18.5 to 22.8) with placebo. Other results relative to the secondary end points did not differ substantially between the groups. Nausea occurred in 46% of participants receiving lixisenatide, and vomiting occurred in 13%.Conclusions: In participants with early Parkinson's disease, lixisenatide therapy resulted in less progression of motor disability than placebo at 12 months in a phase 2 trial but was associated with gastrointestinal side effects. Longer and larger trials are needed to determine the effects and safety of lixisenatide in persons with Parkinson's disease.

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 03/04/2024
• Auteurs : Marianne AbifadelKaousar AhmmedSayera BanuIbrahima CamaraFahmida ChowdhuryDaouda CoulibalyGeorges DabarCédric DananchéRachel DawZakiul HassanMagali HervéAriful IslamFlorence Komurian-PradelJean-Pierre KouaméBourema KouribaJosette Najjar-PelletAndoniaina RakotonaivoFelana Ranaivo-RabetokotanyMandranto RasamoelinaTiavina RasolofoarisonMoussa RiachiMitra Saadatian-ElahiLuc SamisonValentina Sanchez PicotSita SavanéIsmaila TheraAbdoulaye TouréPhilippe Vanhems
• Organismes : Institut National de la Santé et de la Recherche Médicale International Centre for Diarrhoeal Disease Research, Bangladesh Laboratoire de Physique de l'Atmosphère et de l'Océan Siméon Fongang International Centre for Diarrhoeal Disease Research, Bangladesh Institut National de Santé Publique d'Abidjan-INSP Pôle de Santé Publique [Lyon] Hospices Civils de Lyon Santé publique, épidémiologie et écologie évolutive des maladies infectieuses [CIRI] Hospices Civils de Lyon Cardiovasculaire, métabolisme, diabétologie et nutrition Hospices Civils de Lyon Deakin University [Melbourne Burwood] Centre for Integrative Ecology School of Life and Environmental Sciences EcoHealth Alliance [New York] Centre International de Recherche en Infectiologie Fondation Mérieux Centre d'Infectiologie Clinique Charles Mérieux [Bamako, Mali] Centre Hospitalier Manara-Penitra Andohatapenaka [Antananarivo, Madagascar] Santé publique, épidémiologie et écologie évolutive des maladies infectieuses [CIRI] Hospices Civils de Lyon Santé publique, épidémiologie et écologie évolutive des maladies infectieuses [CIRI] Hospices Civils de Lyon
• Publié dans American Journal of Tropical Medicine and Hygiene le 25/10/2020

---

Résumé : ABSTRACT. Despite the numerous articles published on the clinical characteristics and outcomes of COVID-19 with regard to high-income countries, little is known about patients in low- and middle-income countries (LMIC) in this context. The objective of this observational, prospective, hospital-based multicentric study was to describe clinical features and outcomes of laboratory-confirmed COVID-19 patients hospitalized in each of the participating centers in Bangladesh, Guinea, Ivory Coast, Lebanon, Madagascar, and Mali during the first year of the pandemic (March 5, 2020 to May 4, 2021). The study outcome was the clinical severity of COVID-19, defined as hospitalization in intensive care unit or death. Multivariate logistic regression models were performed to identify independent variables associated with disease severity. Overall, 1,096 patients were included. The median age was 49.0 years, ranging from 38.0 in Mali to 63.0 years in Guinea. The overall clinical severity of COVID-19 was 12.3%, ranging from 6.4% in Mali to 18.8% in Guinea. In both groups of patients <60 and ≥60 years old, cardiovascular diseases (adjusted odds ratio [aOR]: 1.99; 95% CI: 1.13–3.50, P = 0.02; aOR: 2.47; 95% CI: 1.33–4.57, P = 0.004) were independently associated with clinical severity, whereas in patients <60 years, diabetes (aOR: 2.13; 95% CI: 1.11–4.10, P = 0.02) was also associated with clinical severity. Our findings suggest that COVID-19-related severity and death in LMICs are mainly driven by older age. However, the presence of chronic diseases can also increase the risk of severity especially in younger patients.

---

Source

---

• Type de publi. : Communication dans un congrès
• Date de publi. : 02/04/2024
• Auteurs : Jean-Philippe MaguéJean-Pierre ChevrotTristan DumasLouise Tarrade
• Organismes : Institut Rhône-Alpin des systèmes complexes Interactions, Corpus, Apprentissages, Représentations LInguistique et DIdactique des Langues Étrangères et Maternelles Interactions, Corpus, Apprentissages, Représentations

---

Fichiers liés : GANESHs2024.pdf

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 02/04/2024
• Auteurs : Béatrice FerversOlivia PérolChristine LassetN MoumjidPauline VidicanPierre SaintignyJuliette TardyJulien BiaudetValérie BonadonaDominique TriviauxPhilippe MarijnenRodolf MongondryAnne Cattey-JavouheyRomain BuonoAmandine BertrandPerrine Marec-BérardChristine Rousset-JablonskiFrank PilleulVeronique ChristopheMagali GirodetDelphine PraudMarie-Laure SolodkyHugo CrochetAbdel AchacheMauricette MichalletChristelle GalvezAnne MiermontDamien SebileauPhilippe ZrounbaSophie BeaupèreThierry PhilipJean-Yves Blay
• Organismes : Centre Léon Bérard [Lyon] Unité Ad Hoc INSERM 000008 "Radiations : Défense, Santé, Environnement" [Lyon] Centre Léon Bérard [Lyon] Unité Ad Hoc INSERM 000008 "Radiations : Défense, Santé, Environnement" [Lyon] Centre Léon Bérard [Lyon] Centre Léon Bérard [Lyon] Parcours santé systémique Unité Ad Hoc INSERM 000008 "Radiations : Défense, Santé, Environnement" [Lyon] Centre Léon Bérard [Lyon] Université Claude Bernard Lyon 1 Centre Léon Bérard [Lyon] Centre de Recherche en Cancérologie de Lyon Dynamiques du Cancer, adaptation et modélisation Unité Ad Hoc INSERM 000008 "Radiations : Défense, Santé, Environnement" [Lyon] Centre Léon Bérard [Lyon] Unité Ad Hoc INSERM 000008 "Radiations : Défense, Santé, Environnement" [Lyon] Centre Léon Bérard [Lyon] Centre Léon Bérard [Lyon] Centre Léon Bérard [Lyon] Centre Léon Bérard [Lyon] Centre Léon Bérard [Lyon] Centre Léon Bérard [Lyon] Centre Léon Bérard [Lyon] Centre Léon Bérard [Lyon] Research on Healthcare Performance Centre Léon Bérard [Lyon] Research on Healthcare Performance Centre Léon Bérard [Lyon] Centre Léon Bérard [Lyon] Centre de Recherche en Acquisition et Traitement de l'Image pour la Santé Centre de Recherche en Cancérologie de Lyon Centre Léon Bérard [Lyon] Research on Healthcare Performance Centre Léon Bérard [Lyon] Centre Léon Bérard [Lyon] Unité Ad Hoc INSERM 000008 "Radiations : Défense, Santé, Environnement" [Lyon] Centre Léon Bérard [Lyon] Centre Léon Bérard [Lyon] Centre Léon Bérard [Lyon] Centre Léon Bérard [Lyon] Centre Léon Bérard [Lyon] Centre Léon Bérard [Lyon] Centre Léon Bérard [Lyon] Centre Léon Bérard [Lyon] UNICANCER Institut Curie [Paris] Centre Léon Bérard [Lyon] UNICANCER Université Claude Bernard Lyon 1
• Publié dans Cancer Prevention Research le 23/10/2020

---

Résumé : This article describes some of the key prevention services in the Leon Berard Comprehensive Cancer Center (CLB) Lyon, France, which are based on clinical prevention services, outreach activities, and collaboration with professional and territorial health communities. In addition, research is embedded at all stages of the prevention continuum, from understanding cancer causes through to the implementation of prevention interventions during and after cancer. Health promotion activities in the community and dedicated outpatient primary cancer prevention services for individuals at increased risk have been implemented. The CLB's experience illustrates how prevention can be integrated into the comprehensive mission of cancer centers, and how in turn, the cancer centers may contribute to bridging the current fragmentation between cancer care and the different components of primary, secondary, and tertiary prevention. With increasing cancer incidence, the shift toward integrated prevention-centered cancer care is not only key for improving population health, but this may also provide a response to the shortage of hospital staff and overcrowding in cancer services, as well as offer opportunities to reduce carbon emissions from cancer care.

---

Fichiers liés : 133.pdf

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 02/04/2024
• Auteurs : Pierre-André JarrotAdrien MirouseSébastien OttavianiSimon CadiouJean-Hugues SalmonEric LiozonSimon ParreauMartin MichaudBenjamin TerrierPierre-Edouard GavandLudovic TrefondVirginie LavoiepierreJeremy KeraenDaniel RekassaBastien BouldoiresThierry WeittenDamien RocheAntoine PouletCaroline CharpinVincent GrobostMarion HermetMagali PallureChloe WackenheimLudovic KarkowskiPierre GrumetThomas RogierNabil BelkefiVincent PestreEmilie BroquetAmélie LeursSophie GautierValérie GrasPierre GiletJan HolubarNadia SivovaNicolas SchleinitzJean-Marc DurandBrice CastelAlexandre PetrierRobin ArcaniBaptiste GramontPhilippe GuilpainHubert LepidiPierre-Jean WeillerJoelle MicallefDavid SaadounGilles Kaplanski
• Organismes : Centre recherche en CardioVasculaire et Nutrition = Center for CardioVascular and Nutrition research Centre recherche en CardioVasculaire et Nutrition = Center for CardioVascular and Nutrition research
• Publié dans Human Vaccines & Immunotherapeutics le 24/10/2020

---

Résumé :

---

Fichiers liés : 174 Polymyalgia rheumatica and giant cell arteritis following COVID-19 vaccination Results from a nationwide survey.pdf

---

Source

---

• Type de publi. : Chapître d'ouvrage
• Date de publi. : 01/04/2024
• Auteurs : Antonio RomanoPhilippe Boula de MareüilJean-Pierre Lai
• Organismes : Laboratorio di Fonetica Sperimentale "Arturo Genre" Traitement du Langage Parlé - LISN GIPSA-Services GIPSA - SYstèmes Linguistiques, Dialectologie et Oralité

---

Source